View More Recent Stories
-
Natera (NTRA) Tops Q3 EPS by 31c; raises outlook
-
Natera (NTRA) PT Raised to $150 at Canaccord Genuity
-
Natera (NTRA) Reports Court Ordered Permanent Injunction Against NeoGenomics' Accused RaDaR Assay
-
Piper Sandler Reiterates Overweight Rating on Natera (NTRA)
-
TD Cowen Reiterates Buy Rating on Natera (NTRA)
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Natera (NTRA) PT Raised to $145 at Canaccord Genuity
-
Natera (NTRA) PT Raised to $145 at TD Cowen
-
Natera (NTRA) PT Raised to $120 at Baird
-
Natera (NTRA) Tops Q2 EPS by 39c, provides guidance
-
TD Cowen Reiterates Buy Rating on Natera (NTRA)
-
Piper Sandler Reiterates Overweight Rating on Natera (NTRA)
-
These stocks offer you exposure to rising demand for fertility treatment – Barclays
-
Natera (NTRA) Announces DECIPHER Phase 2 Trial
-
Wolfe Research Reiterates Outperform Rating on Natera (NTRA)
-
Cabot Wealth shares top 10 stocks picks for this week

